Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Manage your formulary budget
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof|
|Abstract:||A method of detecting and treating malignant and non-malignant tissue abnormalities and lesions of the skin; conjunctiva; respiratory, digestive and vaginal mucosa; endometrium and urothelium; and for ablating the endometrial tissue and treating body fluids, including blood containing suspended abnormal cells, and for treating cancers of the nervous system in which 5-aminolevulinic acid or precursor thereof is administered to the patient in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the abnormal cells, followed by exposure of the abnormal cells to light of photoactivating wavelengths.|
|Inventor(s):||Kennedy; James C. (Kingston, CA), Pottier; Roy H. (Kingston, CA), Reid; Robert L. (Kingston, CA)|
|Assignee:||Queen's University (Kington, CA)|
1. A method for treating or detecting in a patient rapidly growing cells that preferentially accumulate a photoactivatable porphyrin, comprising the steps of administering to said
patient, or contacting said cells with, an effective amount of a precursor of protoporphyrin IX such that said cells accumulate therapeutic or detectable levels of said protoporphyrin IX, and thereafter exposing said cells to light capable of
photoactivating said protoporphyrin IX.
2. The method of claim 1, wherein said light has a wavelength within the absorbance spectrum of said protoporphyrin IX to thereby induce fluorescence in said cells.
3. The method of claim 1, wherein said light has a wavelength in the range from 350-640nm.
4. The method of claim 1, wherein said light has a wavelength in the range from 610-670nm.
5. The method of claim 4, wherein said wavelength of said light is 625 nm.
6. The method of claim 4, wherein said wavelength of said light is 635 nm.
7. The method of claim 1 wherein said rapidly growing cells comprise a lesion selected from the group consisting of a benign, malignant or non-malignant lesion.
8. The method of claim 1, wherein said condition is psoriasis.
9. The method of claim 1, wherein said rapidly growing cells are normal cells or fetal cells.
10. The method of claim 1, wherein said therapeutic method results in palliation of said condition or destruction of said cells associated with said condition.
11. The method of claim 10, wherein said cells are from the endometrium.
12. The method of claim 10, wherein said cells are fetal cells.
13. The method of claim 1, wherein said precursor is 5-aminolevulinic acid.
14. The method of claim 2, wherein said therapeutic method results in the detection of said cells and tissues.
15. The method of claim 1, wherein said rapidly growing cells are malignant or non-malignant tissues selected from the group consisting of exocrine glands and ducts, thymus, spleen, lymph nodes, bone marrow, lymph, blood, nervous tissue and connective tissues.
16. The method of claim 1, wherein said treating comprises treating dysfunctional uterine bleeding, endometriosis, or iron deficiency anemia caused by excessive menstrual bleeding.
17. The method of claim 1, wherein said rapidly growing cells comprise endometrial cells and said treating or detection applies to conditions selected from the group consisting of dysfunctional uterine bleeding, endometriosis, iron deficiency anemia, fertility, contraception, pregnancy, or sites of infection.
18. A method for therapeutically treating a patient's bone marrow or blood cells which contain cells that preferentially accumulate photoactivatable porphyrins, comprising the steps of contacting said bone marrow or blood cells with an effective amount of a precursor of protoporphyrin IX; exposing said bone marrow or blood cells ex-vivo to photoactivating light so as to photoactivate said preferentially accumulating cells and then infusing said exposed bone marrow or blood cells into said patient.
19. The method of claim 18, wherein said cells from bone marrow or blood are removed from said patient before said administration.
20. The method of claim 19, wherein said cells are leukemia blood cells.
21. The method of claim 19, wherein said precursor is 5-aminolevulinic acid.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.